Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
193.16
-0.24 (-0.12%)
Streaming Delayed Price
Updated: 11:33 AM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Nasdaq Turns Higher; Akanda Shares Plunge
March 25, 2024
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
March 25, 2024
Landos Biopharma stock is up on Monday as LABP investors learn about a massive acquisition deal with AbbVie that values it at $137.5 million.
Via
InvestorPlace
The Latest Analyst Ratings For AbbVie
March 22, 2024
Via
Benzinga
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
March 18, 2024
Via
Benzinga
Decoding AbbVie's Options Activity: What's the Big Picture?
March 14, 2024
Via
Benzinga
Crude Oil Moves Higher; US New Home Sales Fall In February
March 25, 2024
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
March 25, 2024
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease.
Via
Benzinga
US Stocks Down; Chicago Fed National Activity Index Rises In February
March 25, 2024
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
March 21, 2024
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
Via
Talk Markets
Healthcare And Biotech Update With Market At 2024 Highs
March 20, 2024
The bull market is intact with technology Stocks dominating, but XLV is up 6.89%YTD.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 18, 2024
Via
Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist
March 17, 2024
Every company faces headwinds eventually. The top ones know how to bounce back.
Via
The Motley Fool
How Much a $1 Million Portfolio Would Pay in Dividends
March 13, 2024
See how to construct a $1 million portfolio.
Via
The Motley Fool
SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster
March 13, 2024
With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors.
Via
InvestorPlace
Topics
ETFs
3 Must-Have Dividend Kings for a Steady Income Stream
March 12, 2024
Discover the dividend kings with constant growth, dominating pharmaceuticals, household products and biotechnology industries.
Via
InvestorPlace
Trouble-Proof Dividend Darlings: 7 Stocks That Keep Paying No Matter What
March 11, 2024
With economic conditions presenting a question mark for the consumer economy, these dividend stocks may shine brightly.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
March 11, 2024
The company tested its psoriatic arthritis drug over 24 weeks against Humira.
Via
Investor's Business Daily
Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
March 11, 2024
Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors.
Via
Benzinga
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
March 11, 2024
There are some great companies at attractive prices in the lucrative pharmaceutical space.
Via
The Motley Fool
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
March 09, 2024
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market.
Via
InvestorPlace
The AI Race Gets Litigious
March 09, 2024
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
March 09, 2024
These businesses can pack a punch in your portfolio over the long run.
Via
The Motley Fool
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...
Via
Benzinga
Exposures
Product Safety
3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates
March 06, 2024
These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
March 06, 2024
Via
Benzinga
The Top 7 Dividend Stocks to Buy in March 2024
March 06, 2024
Bet on these top dividend stocks to buy for a resilient income flow and steady market gains, offering excellent balance.
Via
InvestorPlace
Secure Your Future: 7 Dividend Kings with Solid Growth Potential
March 04, 2024
Here are seven dividend kings that manage to deliver market-beating stock price growth in addition to their reliable, growing dividends.
Via
InvestorPlace
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
March 01, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.